Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) CFO Nelson Sun purchased 10,000 shares of the business's stock in a transaction on Friday, February 14th. The stock was acquired at an average price of $16.00 per share, with a total value of $160,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 99,484 shares in the company, valued at $1,591,744. The trade was a 11.18 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Aardvark Therapeutics Stock Up 9.9 %
NASDAQ:AARD opened at $14.90 on Thursday. Aardvark Therapeutics, Inc. has a fifty-two week low of $11.55 and a fifty-two week high of $16.48.
Aardvark Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
